ABSTRACT
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus responsible for several significant outbreaks of debilitating acute and chronic arthritis and arthralgia over the past decade. These include a recent outbreak in the Caribbean islands and the Americas that caused more than 1 million cases of viral arthralgia. Despite the major impact of CHIKV on global health, viral determinants that promote CHIKV-induced disease are incompletely understood. Most CHIKV strains contain a conserved opal stop codon at the end of the viral nsP3 gene. However, CHIKV strains that encode an arginine codon in place of the opal stop codon have been described, and deep-sequencing analysis of a CHIKV isolate from the Caribbean identified both arginine and opal variants within this strain. Therefore, we hypothesized that the introduction of the arginine mutation in place of the opal termination codon may influence CHIKV virulence. We tested this by introducing the arginine mutation into a well-characterized infectious clone of a CHIKV strain from Sri Lanka and designated this virus Opal524R. This mutation did not impair viral replication kinetics in vitro or in vivo. Despite this, the Opal524R virus induced significantly less swelling, inflammation, and damage within the feet and ankles of infected mice. Further, we observed delayed induction of proinflammatory cytokines and chemokines, as well as reduced CD4+ T cell and NK cell recruitment compared to those in the parental strain. Therefore, the opal termination codon plays an important role in CHIKV pathogenesis, independently of effects on viral replication.
KEYWORDS: alphavirus, chikungunya, opal stop codon, viral pathogenesis
IMPORTANCE
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes significant outbreaks of viral arthralgia. Studies with CHIKV and other alphaviruses demonstrated that the opal termination codon within nsP3 is highly conserved. However, some strains of CHIKV and other alphaviruses contain mutations in the opal termination codon. These mutations alter the virulence of related alphaviruses in mammalian and mosquito hosts. Here, we report that a clinical isolate of a CHIKV strain from the recent outbreak in the Caribbean islands contains a mixture of viruses encoding either the opal termination codon or an arginine mutation. Mutating the opal stop codon to an arginine residue attenuates CHIKV-induced disease in a mouse model. Compared to infection with the opal-containing parental virus, infection with the arginine mutant causes limited swelling and inflammation, as well as dampened recruitment of immune mediators of pathology, including CD4+ T cells and NK cells. We propose that the opal termination codon plays an essential role in the induction of severe CHIKV disease.
INTRODUCTION
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus in the Togaviridae family that is associated with large-scale outbreaks. Infection with CHIKV leads to a febrile illness characterized by severe acute and chronic arthralgia. In 2005, CHIKV reemerged during an outbreak on La Réunion Island off the coast of Africa. This epidemic affected one-third of the island’s population and resulted in an estimated US $66.5 billion in medical expenses (1). In 2013, locally acquired transmission of CHIKV was reported for the first time in the Western Hemisphere on the island of St. Martin in the Caribbean. This resulted in over 1 million suspected cases and 20,000 confirmed cases of CHIKV infection throughout North, South, and Central America (2). Currently, there are no vaccines or antivirals available to prevent or treat CHIKV infection.
The alphavirus genome is encompassed by a positive-sense single-stranded RNA of approximately 11.7 kb (reviewed in reference 3). The nonstructural proteins (nsPs) are encoded at the 5′ end of the genome and translated as a polyprotein precursor that is posttranslationally processed to produce the mature nsP1-4 proteins. During the initial stages of infection, the major nonstructural protein species consist of the polyprotein precursor nsP123 and nsP4. The latter is rapidly cleaved from the polyprotein and is found solely in its mature state. A conserved opal stop codon is located within the C terminus of the nsP3 gene in several alphaviruses (reviewed in reference 3). Read-through of the opal stop codon during translation occurs infrequently and produces full-length nsP1234. Consequently, stoichiometric concentrations of nsP4 are estimated to be much lower than those of the other nonstructural proteins (4). The polyprotein nsP123 and cleaved nsP4 mediate synthesis of the viral negative-sense RNA, which serves as a template for genomic RNA production. Upon further cleavage into the mature proteins nsP1, nsP2, nsP3, and nsP4, replication switches to replicate positive-sense genomic RNA and transcribe subgenomic RNA. The structural polyprotein is translated from subgenomic RNA and consists of capsid, E1, E2, E3, 6K, and transframe (TF) (5, 6). Capsid is cleaved autocatalytically, and the structural proteins are further processed in the endoplasmic reticulum (ER) (7, 8). Together, these proteins assemble around genomic RNA and form virions at the plasma membrane.
Several studies have identified key viral determinants of alphavirus pathogenesis within untranslated regions (UTRs), nonstructural proteins, and structural proteins (9–12). Mutations within the viral nonstructural proteins and envelope glycoproteins modulate type I interferon (13–16), host cell shutoff (17), and the stress response (18, 19). More recently, other work has explored the sequence diversity within clinical isolates of CHIKV from the Caribbean outbreak. Through this analysis, a novel 3′ UTR sequence that allowed for enhanced replication in mosquito cells was discovered (20). These data corroborate studies of both CHIKV and other alphaviruses that indicate that mutations in the UTRs can have profound impacts on replication in mosquito vectors (11, 12). However, studies on CHIKV-specific determinants of disease have been fairly limited and have focused largely on host determinants that influence development of severe disease (21, 22). Of those viral determinants that have been identified, a mutation in the viral envelope (E1-A226V) played a major role in permitting CHIKV replication within a novel mosquito vector, which allowed for an unprecedented expansion of CHIKV into naive human populations (10). All together, these data provide a strong rationale for identifying viral determinants of severe CHIKV disease.
Like many alphaviruses, the majority of CHIKV strains encode an opal termination codon at the 3′ end of nsP3 (20, 23, 24). However, some CHIKV isolates encode an arginine residue in place of the opal termination codon, such as SGP007, a CHIKV isolate from a patient in Singapore (25). Studies with Sindbis virus (SINV) have shown that the opal stop codon regulates both the amount of nsP4 produced during infection (4) and posttranslational cleavage of nsP34 (26). During translation of the nonstructural polyprotein during the first few hours after infection, full-length nsP1234 comprises only 5 to 20% of the polyprotein products translated, while nsP123 is produced to much greater abundance (4). Further, introduction of the arginine mutation into SINV results in accumulation of uncleaved nsP34 instead of mature nsP3 (26). O’nyong-nyong virus (ONN), a closely related alphavirus, encodes either an opal termination codon or an arginine codon (27, 28). One study demonstrated that the opal termination codon confers a fitness advantage for ONN in Anopheles gambiae, its mosquito host (28). However, infection with a SINV strain that naturally encodes a cysteine residue in place of the opal stop codon leads to severe morbidity and mortality in mice (9). Together, these data suggest that the presence of an amino acid residue in place of the opal stop codon may alter CHIKV pathogenesis.
In this study, we examined a patient isolate of the Caribbean strain of CHIKV for novel viral variants that could impact pathogenesis. We found that this strain of CHIKV, which was isolated in St. Martin, encodes both the conserved opal termination codon and the arginine mutation. Therefore, we tested how mutations in the opal stop codon impact CHIKV replication and disease. To this end, we introduced the arginine mutation into the infectious clone of a Sri Lankan strain of CHIKV that naturally encodes the opal stop codon (29). The resulting virus was designated Opal524R. We found that the presence of the arginine mutation did not significantly impact viral replication in cultured cells or in target tissues in vivo, which is in contrast to prior findings with SINV (26). Strikingly, the Opal524R mutant caused less-severe disease in a mouse model than the wild-type virus, as measured by decreased swelling and histopathological damage in the footpads and ankle joints of infected animals. The Opal524R mutant exhibited delayed induction of proinflammatory cytokine and chemokine production and a corresponding reduction of inflammatory leukocyte recruitment into the feet and ankle joints. Therefore, these data indicate that the presence of an opal termination codon within nsP3 has a major impact on CHIKV-induced disease severity.
RESULTS
Identification of the Opal524R mutation in the Caribbean strain of CHIKV.
We performed deep sequencing of a clinical isolate derived from a human patient from the island of St. Martin obtained during the CHIKV outbreak in 2013 (GenBank accession no. MG208125). Through this analysis, we identified a thymine-to-cytosine single nucleotide polymorphism (SNP) within the opal termination codon resulting in a coding change to an arginine residue (data not shown). This SNP was found in nearly 70% of reads, making the arginine codon the dominant variant in this isolate. To examine the role of the opal stop codon in CHIKV pathogenesis, we introduced an arginine codon in place of the opal termination codon in an infectious clone of a Sri Lankan CHIKV strain that is associated with severe disease in mouse models of CHIKV-induced arthritis (29). The resulting mutant virus, which was designated Opal524R, was then characterized to test whether replacement of the opal termination codon had any impact on viral replication or the pathogenesis of CHIKV-induced arthritis.
The Opal524R mutation does not adversely affect CHIKV replication.
Mutations in the opal termination codon and nearby sequence adversely impact multiple aspects of replication in some SINV and CHIKV strains (4, 25, 26, 30). Therefore, we initially tested whether the Opal524R mutation had any impact on viral replication in vitro. We found no defects in Opal524R growth at high or low multiplicities of infection (MOI) in Vero cells (Fig. 1A and B) or at a low MOI in Aedes albopictus C6/36 cells (Fig. 1D). In fact, the Opal524R mutant showed enhanced replication compared to that of the wild-type virus at early times postinfection in multistep growth curves (Fig. 1B), which is consistent with prior findings for ONN (28). Furthermore, we found that the Opal524R mutant produces genomic RNA with kinetics and abundances similar to those of the parental virus (Fig. 1C). However, Vero cells exhibit impaired interferon signaling. Therefore, we further tested the Opal524R mutant for replication defects in a human cell line with intact innate immunity. When MRC-5 cells, which have a functional type I IFN response, were infected at an MOI of 0.01, we found no defects in replication at early or late times postinfection (Fig. 1E). These results indicate that the presence of the arginine residue in place of the opal termination codon does not overtly impair CHIKV replication in vitro.
The Opal524R mutation alters nsP4 processing.
Previous reports indicated that mutation of the opal stop codon to an amino acid in SINV can impact viral protein production or processing (26, 30). Therefore, we measured levels of nsP3 and E2 in Vero cells infected with either the wild-type virus or the Opal524R mutant. Measurable levels of mature nsP3 were observed beginning at 8 h postinfection for both viruses, although levels were elevated for the Opal524R mutant compared to those of the wild-type virus at this time point (Fig. 2A and B). However, the monoclonal antibody used in these assays appears to be unable to detect nsP3 in the context of nsP123, nsP1234, or nsP34, so we were unable to assess the efficiency of proteolytic cleavage of nsP3 from the nonstructural polyprotein. Both the mature and immature isoforms of E2 were detectable at comparable levels for the two viruses, beginning at 8 h postinfection. We next tested whether nsP4 production or processing was altered by the Opal524R mutation. To measure different isoforms of nsP4, we generated CHIKV replicons with C-terminal FLAG tags after nsP4 for both the wild-type and Opal524R viruses. BHK-21 cells were electroporated with RNA from either replicon, and nsP4 production was measured using antibodies against FLAG. The Opal524R mutant produced higher levels of mature nsP4-FLAG beginning at 2 h postinfection and continuing through 8 h postinfection, suggesting that the Opal524R mutation enhances translational read-through of the nsP4 open reading frame (Fig. 2C and D). In addition, levels of immature nsP34-FLAG were also higher for the Opal524R virus at all time points measured (Fig. 2C). Overall, these results suggest that enhanced translational read-through by the Opal524R mutant results in increased levels of both the nsP34-FLAG precursor and mature nsP4-FLAG within infected cells.
The Opal524R mutant fails to induce severe disease in a mouse model.
We next tested whether the Opal524R mutant exhibited altered virulence in vivo using a mouse model of CHIKV-induced disease. In this model, footpad infection with wild-type CHIKV results in biphasic footpad swelling and tenosynovitis within the inoculated foot (29). The Opal524R mutant induced footpad swelling over that in mock-infected animals; however, the level of swelling was significantly reduced compared to that caused by the wild-type virus at both early and late times postinfection (Fig. 3A). This suggests that the Opal524R mutant is less virulent in vivo than the parental virus in a mouse model of disease.
Damage and inflammation is reduced in the ankle joints of Opal524R-infected mice.
To further analyze the impact of the arginine mutation on CHIKV-induced disease, mock-infected or CHIKV-infected mice were sacrificed at 7 days postinfection and inflammatory pathology was assessed within the feet and ankle joints on hematoxylin-and-eosin-stained sections. We observed reduced inflammatory cell infiltration within the joints of mice infected with the Opal524R virus, consistent with the attenuation in virus-induced swelling (Fig. 3B). Blind histological analysis also indicated that infection with the Opal524R mutant resulted in less damage within ankle joints and tendons (Fig. 3C). To more closely assess inflammation within joint tissues, we stained for nitrotyrosine accumulation within the ankle joints at day 7 postinfection (Fig. 3D). Under conditions of oxidative stress, superoxide and nitric oxide react to form the free radical peroxynitrite, which causes nitration of tyrosine residues (31, 32). Nitrotyrosine accumulation is a stable indicator of oxidative stress associated with several inflammatory disease states, including celiac disease, rheumatoid arthritis, and CHIKV infection (31–35). We previously found that wild-type CHIKV infection induces oxidative stress within infected feet, as indicated by a pronounced accumulation of nitrotyrosine within these tissues (36). Consistently with these earlier results, infection with wild-type CHIKV resulted in high levels of nitrotyrosine staining in muscle, tendon, and the synovial lining of the joints (Fig. 3D). However, we observed a marked decrease in nitrotyrosine accumulation in all of these regions of the feet and ankle joints of mice infected with the Opal524R mutant compared to that found in mice infected with the parental virus. Together, these data support the conclusion that the opal termination codon contributes to CHIKV-induced disease in vivo.
The Opal524R mutant replicates efficiently in vivo.
Although the Opal524R mutant replicated efficiently in vitro, one likely explanation for the differences in disease induction between these two viruses might be a general defect in viral replication in vivo. To address this, we measured replication within both proximal and distal tissues at several times postinfection (Fig. 4). We found that the Opal524R mutant replicates efficiently in all target tissues, including the ipsilateral and contralateral foot and quadriceps muscles and popliteal lymph nodes. Levels of viremia in serum were also equivalent between the two viruses. Therefore, while viral replication was transiently reduced in the contralateral foot at day 3 postinfection (Fig. 4B), these results suggest that the differences in virus-induced swelling and pathology in the inoculated foot cannot be explained by differential in vivo replication. It is also possible that the Opal524R virus may revert back to wild type in vivo, thereby leading to equivalent levels of viral replication. To test this, subsets of mice (5 mice infected with the wild type; 7 mice infected with Opal524R) were sacrificed at 24 h postinfection and RNA was extracted from the inoculated foot. Sequencing across the nsP3 gene confirmed that the Opal524R mutation is stable and did not revert at 24 h postinfection in vivo.
Immune cell recruitment to the site of infection is limited during Opal524R infection.
Specific immune cell populations, including monocytes, CD4+ T cells, and NK (natural killer) cells, infiltrate the site of CHIKV infection in vivo and mediate disease (37, 38). Therefore, the differences in pathology that we observed might reflect differences in levels of recruitment of specific immune cell mediators into the infected joints. We tested this by measuring immune cell recruitment to the site of infection by flow cytometry at day 7 postinfection. The prevalences of several types of immune cells differed when mice were infected with the Opal524R mutant. Recruitment of CD4+ T cells and NK cells, two cell populations that contribute to CHIKV-induced inflammatory pathology (37, 38), were reduced in Opal524R-infected mice (Fig. 5A). Overall numbers of CD8+ T cells and B cells were also reduced following Opal524R infection, despite the fact that these cell populations have not been implicated as drivers of CHIKV-induced inflammation (Fig. 5A). Interestingly, while monocytes have also been implicated in driving CHIKV pathogenesis (38), we did not observe statistically significant differences in levels of recruitment of monocytes between the Opal524R mutant (based on overall cell numbers) and the wild type. In fact, we found that monocytes comprise a greater percentage of total infiltrating leukocytes (defined as leukocyte common antigen-positive [LCA+] cells) during infection with the Opal524R virus than during infection with the wild type (Fig. 5B). Overall, these data suggest that attenuation of swelling during Opal524R infection may be due in part to a failure to recruit high levels of CD4+ T cells and NK cells but cannot be explained by differences in monocyte recruitment.
Proinflammatory cytokines and chemokines are produced to lower levels at day 1 postinfection.
Persistent arthralgia in CHIKV-infected patients is characterized by high levels of certain proinflammatory cytokines, such as interleukin 6 (IL-6), MIG (monokine induced by interferon gamma), and IP-10 (interferon gamma-induced protein 10) (39, 40). Based on the differences described in inflammatory cell recruitment, we hypothesized that differential chemokine activation during Opal524R infection accounts for the lower numbers of CD4+ T cells and NK cells recruited to the site of infection. To address this question, we measured cytokine production within the ipsilateral foot early during infection. Infection with wild-type CHIKV induced production of several cytokines at day 1 postinfection, including the proinflammatory cytokines tumor necrosis factor alpha (TNF-α), IL12p70, and the chemokines CXCL9 (CXC-motif chemokine 9) (MIG), CXCL10 (IP-10), CCL3 (CC-motif chemokine 3) (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), and CCL7 (MCP3) (Fig. 6A). Protein levels for all of these cytokines were significantly reduced during Opal524R infection. Of these, CXCL9 (MIG), CXCL10 (IP-10), and CCL4 (MIP-1β) are known T cell and NK cell chemoattractants. Further, although we did not observe significant differences in monocyte recruitment to the footpad, CCL3, CCL4, CCL7, and CXCL10 are all known monocyte chemoattractants that were also significantly reduced during Opal524R infection. This difference in early chemokine production is consistent with our findings that CD4+ T cells, CD8+ T cells, and NK cells are less efficiently recruited during Opal524R infection.
Levels of cytokine production are comparable between the wild type and Opal524R at day 2 postinfection.
At day 2 postinfection, many of the cytokines induced by wild-type infection were induced to comparable levels by Opal524R infection, with two exceptions. TNF-α and CCL4 (MIP-1β) continued to be produced to significantly lower levels during Opal524R infection (Fig. 6B). Wild-type infection also induced IL-6, CCL2 (MCP-1), and CXCL1 at day 2 postinfection and suppressed IL-15 production compared to levels in mock-infected animals. By comparison, CCL2 and IL-6 were significantly reduced during Opal524R infection at day 2 postinfection. Together, these data suggest that there is a delay in activation of many proinflammatory cytokines early during Opal524R infection. Notably, TNF-α and CCL4 levels were significantly lower during Opal524R infection at days 1 and 2 postinfection (Fig. 6). These differences may account for the reduction in inflammatory cell infiltration and pathology observed in the joint during infection with the Opal524R mutant.
Cytokine induction is also diminished at the transcript level.
We further confirmed differences in cytokine production by measuring mRNA transcript levels for a subset of cytokines by quantitative real-time reverse transcription PCR (qRT-PCR). In mice infected with wild-type virus, transcripts were only modestly elevated at day 1 postinfection for CCL2, CCL4, IL-6, and CXCL9, while CXCL10 transcripts were very highly elevated relative to levels in mock-infected mice (Fig. 7A). Consistently with the reduction in protein levels observed, CCL4 and CXCL10 transcripts were significantly reduced in Opal524R-infected mice relative to those in wild-type-infected mice. TNF-α mRNA levels were not significantly different from those in mock-infected mice for either virus. At day 2 postinfection, both TNF-α and IL-6 transcripts were moderately induced by wild-type virus, while CCL2, CCL4, CXCL9, and CXCL10 mRNA levels were all highly elevated by wild-type virus infection (Fig. 7B). There was a significant reduction in TNF-α, IL-6, and CXCL10 transcripts during Opal524R infection at this time point. These data support the conclusion that the Opal524R mutant differentially induces proinflammatory cytokines and chemokines.
DISCUSSION
There is presently no consensus on the requirement for the opal termination codon in alphavirus replication. The AR86 strain of SINV and the SFV4 and prototype strains of Semliki Forest virus (SFV) tolerate coding changes in place of the opal termination codon (9, 41), and these mutations can enhance virulence. Furthermore, ONN replication in vitro is actually enhanced by introduction of an arginine codon in place of the opal stop codon (28). Conversely, mutations to the opal termination codon and nearby sequence adversely impact multiple aspects of replication in other SINV strains (4, 26, 30). Specifically, translational read-through of the opal codon, proteolytic cleavage of nsP34, production of genomic RNA, and production of infectious particles in vitro are all negatively impacted when the opal termination codon or the cytosine base immediately downstream are mutated. Similarly, another study found that nonisogenic CHIKV strains encoding the opal stop codon replicate more efficiently in vitro than arginine-containing strains (25).
In this study, we identified a mutation of the opal termination codon to an arginine residue in a patient-derived isolate of CHIKV from the recent Caribbean outbreak, isolated on St. Martin. One other CHIKV sequence available from a patient on St. Martin also contains the Opal524R mutation (GenBank accession number KX262991). However, sequences from patient isolates from other regions of the Caribbean outbreak contain the opal stop codon. Specifically, 10 isolates analyzed from Haiti (GenBank accession numbers KX702401.1, KX702402, and KY415978 to KY415985) and 15 isolates analyzed from Puerto Rico (GenBank accession numbers MF001505 to MF001519) all contain the opal stop codon (42). This may suggest that early isolates of CHIKV from the Caribbean outbreak contained the Opal524R mutation but that this was lost over time. Further sequence analysis of more patient samples from different stages of the outbreak will be required to ascertain whether this occurred.
Earlier work demonstrated that the Opal524R mutation can be tolerated in isolates of CHIKV from other regions (e.g., SGP007, a patient isolate from Singapore) but that the SGP007 isolate exhibited reduced replication efficiency relative to those of other CHIKV isolates (SGP011, another patient isolate from Singapore, and IMT, a La Réunion strain) (25). Our study instead demonstrates that the Opal524R mutation can be efficiently tolerated in the context of CHIKV with no cost to overall replication efficiency. However, there are important differences between these studies that might account for these discrepancies. Our study utilized virus stocks derived from infectious clones, so only the effect of the Opal524R mutation was considered. In contrast, these earlier comparative analyses were based on patient isolates. In particular, the SGP007 strain contains six additional coding changes from the sequences of IMT and SGP011 that may interact with the Opal524R mutation to contribute to the observed replication defects. Together, these reports may suggest that additional linked mutations are required for optimal replication efficiency. Further investigation of such potential linked mutations is under way.
This study demonstrates that the conserved opal termination codon within CHIKV is required for induction of severe disease in a mouse model of CHIKV-induced arthritis. Mutations to the opal stop codon enhance virulence in the AR86 strain of SINV (9) and in the SFV4 strain of Semliki Forest virus (41), but the data reported herein instead suggest that the arginine mutation found in CHIKV does not increase disease severity or replication in a mouse model of disease. These results illustrate that mutations to the opal stop codon may have contrasting effects on the virulences of different alphavirus family members, while also raising the possibility that such mutations may impact other aspects of the CHIKV replication cycle. Furthermore, understanding how the opal termination codon modulates alphavirus virulence and the mechanisms underlying this effect may have important implications for the development of live attenuated vaccines against viruses such as CHIKV. As such, additional studies of the molecular mechanism by which the opal stop codon contributes to CHIKV virulence are warranted.
In this study, we demonstrate that the opal termination codon plays an important role in CHIKV pathogenesis. We observed striking differences between the Opal524R mutant and the parental virus in both immune pathology and tissue inflammation. However, these effects occur independently of any measurable effect on viral replication. Our results do suggest that the Opal524R mutation alters translational read-through of nsP4, resulting in increased expression of both mature nsP4 and the nsP34 cleavage intermediate within infected cells. Further studies are necessary to discern whether these differences in nonstructural protein processing can account for differential disease outcomes. For example, although we did not observe differences in genomic RNA expression in infected cells (Fig. 1C) or altered viral replication in IFN-competent cells (Fig. 1E) or in vivo (Fig. 4), we cannot rule out the possibility that increased levels of nsP4 expression alter viral RNA synthesis. These differences may enhance innate immune sensing or cellular stress responses, thereby boosting the early immune response and limiting pathological downstream immune responses. Additional studies to test these possibilities are underway.
While we did not see any negative impact of the Opal524R mutation on replication in an Aedes albopictus cell line, C6/36, we cannot rule out the possibility that this mutation will impact other aspects of the viral replication cycle in mosquito vectors. As noted above, studies with the closely related alphavirus ONN have identified the presence of both opal and arginine codons in nsP3 (27, 28). ONN strains carrying the arginine codon exhibited a growth advantage in vitro, which is similar to our findings with CHIKV (Fig. 1). However, these studies demonstrated that the opal termination codon enhanced infection in the mosquito vector, which may explain why the vast majority of CHIKV isolates sequenced to date encode the opal termination codon, rather than arginine, at nsP3 position 524. Therefore, additional studies are clearly needed to directly test the potential role of the opal termination codon in CHIKV replication in mosquito vectors.
Currently, there are no effective vaccines available to protect against CHIKV-induced disease. In this study, we show that mutation of the opal stop codon produces a viable mutant that fails to induce severe disease. CHIKV infection in human patients is characterized by induction of several proinflammatory cytokine and chemokine markers, including gamma interferon (IFN-γ), TNF-α, IP-10, and IL-6 (39, 40, 43). Our group and others have demonstrated that similarly high production of these and other cytokines occur very early during CHIKV infection in a mouse model (38–40). These cytokines are induced more slowly during infection with the Opal524R mutant. Therefore, inclusion of opal stop codon mutations within live attenuated CHIKV vaccines containing other attenuating mutations may represent a reasonable strategy to generate a protective immune response. However, additional studies are needed to assess both the safety and the stability of such live attenuated viruses.
In addition to their potential for application in vaccine design, our results may have implications for the development of CHIKV therapeutics. A recent study by Ashbrook et al. found that inhibitors of sodium-potassium ATPases antagonize CHIKV replication and that drug-resistant variants often contain mutations in the opal termination codon (44). Drug-resistant variants containing the Opal524R mutation were also obtained when CHIKV was instead passaged in the presence of difluoromethylornithine (DFMO), a drug that inhibits polyamine biosynthesis and thereby restricts viral replication (45, 46). Interestingly, the Opal524R mutant did not replicate as well as the parental strain in either Aedes albopictus mosquitos or zebrafish, but when combined with additional drug-resistant mutations, the Opal524R mutation enhances replication in vivo (46). Although these drug-resistant variants have not, to our knowledge, been tested for virulence in a mouse model, our results suggest that these viruses would cause less tissue damage than the parental virus. Therefore, antiviral therapies that result in coding changes to the CHIKV opal stop codon may have the added benefit of selection for less virulent variants.
In summary, our results demonstrate that the opal termination codon plays an essential role in promoting the development of CHIKV-induced arthritis independently of effects on viral replication. Most CHIKV isolates sequenced to date contain opal termination codons at nsP3 position 524; however, we observed no negative impact of the arginine mutation on viral replication. Taken together, these results suggest that the opal termination codon plays an essential role in regulating multiple aspects of the CHIKV replication cycle while also promoting CHIKV-induced inflammatory pathology.
MATERIALS AND METHODS
Viruses and cells.
All infectious work with CHIKV was performed under biological safety level 3 conditions using approved standard operating procedures. The clinical isolate of the Caribbean strain of CHIKV used in this study (GenBank accession no. MG208125) was provided by Michael Diamond (Washington University) and was amplified three times in Vero cells prior to receipt by our lab. This isolate was originally obtained from a human patient on the island of St. Martin during the 2013 outbreak and acquired from the World Reference Center for Emerging Viruses and Arboviruses (University of Texas Medical Branch). Virus stocks were amplified in the Aedes albopictus C6/36 cell line. The parental strain of CHIKV used in this study was generated from the clinical isolate SL15649, which originated in Sri Lanka (29). The infectious clone pMH56.2 encodes the full-length genome of this isolate and has been previously described (36). An infectious clone for the mutant virus Opal524R was generated through site-directed mutagenesis. Specifically, primer sets encoding the Opal524R mutation (forward, 5′GAGAAGCCCGGGACGCAGAAAAAG; reverse, 5′GACCTGGACCGGTGTCCGACGAGAATATATACCCACCTGCCCTGTCTAGTCGTAACTC) were used. This amplicon was ligated into the pMH56.2 plasmid backbone. The entire ligated region of the purified, clonal plasmid was sequenced to confirm that no spurious mutations were introduced. Virus stocks from both the wild-type and Opal524R mutant CHIKV strains were produced from electroporation of in vitro-transcribed RNA of each infectious clone (mMessage mMachine SP6 transcription kit; Life Technologies, Inc.) into baby hamster kidney (BHK-21) cells (ATCC CCL-10). African green monkey Vero cells (ATCC CCL-81), human lung fibroblast MRC-5 cells (ATCC CCL-171), and A. albopictus C6/36 cells (ATCC CRL-1660) were used to obtain growth curves. Vero cells were used to perform all plaque assays.
Mice.
All mice used in this study were C57BL/6J mice purchased from the Jackson Laboratory and bred in house. Twenty-four-day-old mice were inoculated subcutaneously in the left rear footpad with 100 PFU of CHIKV in phosphate-buffered saline (PBS) supplemented with 1% fetal bovine serum (FBS). Mock-infected mice were inoculated with diluent alone. Mice were weighed daily and monitored for clinical signs of disease. Footpad swelling was measured using calipers. Mouse sacrifice was performed using isoflurane (Attane; Minrad, Inc.) overdose. Animal husbandry and experiments were conducted under biosafety level 3 conditions and followed approved guidelines set forth by the University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee.
Sequencing of a CHIKV isolate.
The Caribbean isolate of CHIKV used in this study was amplified once on C6/36 cells. At 30 h postinfection, supernatants were collected and virus was purified on a 20% sucrose gradient by ultracentrifugation at 24,000 × g at 4°C overnight. Purified virus was resuspended in 1× PBS. RNA was isolated from purified virus preparations by TRIzol extraction (Ambion). Random priming was performed by annealing random primer 9 (New England Biolabs) to total RNA samples. cDNA was reverse transcribed using SuperScript II (Thermo, Fisher Scientific). Double-stranded DNA (dsDNA) was then produced by use of NEBNext mRNA second-strand synthesis module (New England Biolabs), and dsDNA was purified using a PureLink PCR microkit (Thermo, Fisher Scientific) according to standard procedures. Libraries were created using a Nextera XT DNA library preparation kit and sequenced on a MiSeq desktop sequencer using MiSeq reagent kit v2 (300 cycles) (Illumina). Coverage of the site analyzed included 35,377 reads.
Growth curves.
Vero and C6/36 cells were infected in complete medium in triplicate at the indicated multiplicities of infection at 37°C or 28°C, respectively. At 1 h postinfection, inoculum was removed and cells were rinsed three times with PBS. Medium was replenished, and cells were incubated at 37°C or 28°C. At the times postinfection indicated in the figures, the supernatant was collected and stored at −80°C and medium was replenished to maintain a total volume of 1 ml per well.
Virus titers.
The titers of all virus stocks, cellular supernatants, and tissue homogenates were determined by standard plaque assay on Vero cells. At the times postinfection indicated in the figures, mice were sacrificed by isoflurane overdose and perfused via intracardial injection with 1× PBS. Tissues designated for titration were harvested in 1× PBS and homogenized. All samples were stored at −80°C until the time of plaque assay.
Sequencing of the Opal524R mutation in infected tissues.
Mice were sacrificed at 24 h postinfection, and the inoculated foot was removed. RNA was extracted from tissues using TRIzol (Ambion). Tissues were dissociated by homogenization prior to RNA extraction. Superscript III reverse transcriptase (Invitrogen) was used to generate cDNA by random priming from a total of 10 μg RNA from each sample. PCR was performed using Phusion polymerase (New England Biolabs) with primers flanking the opal stop codon to generate short amplicons (1 PCR per mouse; 5 mice for wild-type infections and 7 mice for Opal524R infections) that were analyzed by standard Sanger sequencing.
Detection of nsP4.
A replicon plasmid that contains the pMH56.2 backbone encoding GFP in place of the structural genes was used. The Opal524R mutation was introduced into the replicon by restriction digestion of the Opal524R infectious clone and ligation into the replicon plasmid. A 3× FLAG tag was cloned at the C terminus of nsP4 in a two-step fusion PCR using the following primer sets: 5′CGGACACCGGTCCAGGTCATTTAC (forward), 5′CTACTTGTCATCGTCATCCTTGTAATCGATGTCATGATCTTTATAATCACCGTCAGGTCTTTGTAGTCTTTAGGACCGCCGTACAAAGTTATG (reverse 1), and 5′CACCATGGCGCGCCTGTAGCTGATTAGTGTTTAGATACTTGCTGTCGGCTTCTGCAAAATAGGTAGCTGTAGTGCGTACCTACTTGTCATCGTCATCCT (reverse 2). All constructs were sequenced across the opal stop codon and FLAG tag to confirm that no spurious mutations were introduced. RNA was in vitro transcribed from linearized plasmids (mMessage mMachine SP6 transcription kit; Life Technologies, Inc.) and purified by lithium chloride extraction. For each replicon, a total of 10 μg RNA was electroporated into BHK-21 cells.
Western blotting.
Cells were rinsed in PBS, lysed in radioimmunoprecipitation assay (RIPA) buffer, and heated at 95°C for 5 min to ensure inactivation of infectious material. Lysates were clarified by centrifugation at 15,000 × g for 10 min, and protein was quantified by Bradford assay. Loading dye was added to equal quantities of protein from each sample, and these were resolved on SDS-PAGE gels. Protein was transferred onto polyvinylidene difluoride (PVDF) membranes, blocked for 1 h in 5 or 10% milk in Tris-buffered saline with Tween 20 (TBS-T), and probed overnight with the following antibodies: CHIKV nsP3 (mouse monoclonal, 1:500; produced in collaboration with Mary Ann Accavitti-Loper, University of Alabama Birmingham), CHIKV E2 (mouse monoclonal, 1:1,000; provided by Michael Diamond, Washington University), FLAG M2 (mouse monoclonal, 1:1,000; Sigma-Aldrich), and actin (goat monoclonal, 1:1,000; Santa Cruz Biotechnology). Secondary antibodies conjugated to horseradish peroxidase (HRP) were used against mouse (GE Healthcare) and goat (Sigma) primary antibodies.
Densitometry analyses.
Bands were quantified for mature E2, nsP3, nsP34, or nsP4, where indicated, using ImageJ software (National Institutes of Health; version 1.48). Band densities were normalized to internal lane background densities. Band densities for individual viral proteins were then normalized to actin levels. Where indicated, band densities for duplicate lanes of an individual experiment were averaged.
Histological analyses.
Mice were sacrificed and perfused intracardially with 4% paraformaldehyde. Tissues were embedded in paraffin, and 5-μm sections were prepared. Tissues were stained with hematoxylin and eosin. Slides were deidentified and scored for inflammation and musculoskeletal tissue damage as described previously (36). Slides were imaged using an Olympus BX43 model microscope with CellSens software.
Immunohistochemistry.
Immunohistochemical analysis of nitrotyrosine levels has been described previously (36). Briefly, tissues were fixed in 4% paraformaldehyde and embedded in paraffin, and 5-μm sections were prepared. Slides were deparaffinized with xylene, blocked in 10% donkey serum (Jackson ImmunoResearch), and stained with antibody for nitrotyrosine (Millipore). Biotinylated secondary antibodies were detected with streptavidin–DyLight-594 conjugate, and slides were mounted with ProLong antifade reagent gold (Invitrogen). Slides were imaged with an Olympus BX60 fluorescence microscope; images were collected with the iVision v.4.0.0 software (BioVision Technologies).
Flow cytometry.
Mice were sacrificed and perfused with 1× PBS, and the ipsilateral foot was harvested in digestion medium (complete RPMI medium supplemented with collagenase A and DNase). Spleen was harvested from mock-infected mice in 1× PBS and used for control stains. All tissues were minced, and feet were further dissociated by shaking them for 1.5 to 2 h at 37°C. Tissues were then rinsed, lysed in ACK (ammonium chloride potassium) buffer, rinsed again, and plated in HFA (Hanks’ balanced salt solution [HBSS] supplemented with 1% FBS and 1% sodium azide). Tissues were stained for 30 min at 4°C with the following antibodies: fluorescein isothiocyanate (FITC)-anti F4/80 (EBioscience), phycoerythrin (PE)-anti CD115 (EBioscience), PETR (Texas Red with R-phycoerythrin)-anti CD11c (Invitrogen), peridinin chlorophyll protein (PerCP)-Cy5.5-anti Ly6C (BioLegend), PE-Cy7-anti LCA (EBioscience), eF450-anti CD11b (EBioscience), allophycocyanin (APC)-anti GR-1 (BioLegend), APCeF780-anti major histocompatibility complex class IIc (MHC-IIc) (EBioscience), FITC-anti CD3e (EBioscience), PE-anti NK1.1 (EBioscience), PETR-anti CD4 (Invitrogen), PerCP-anti CD8 (BD), PE-Cy7-anti LCA (EBioscience), and APC-anti B220 (EBioscience). Flow cytometry was performed on a Beckman Coulter, Inc., CyAn advanced digital processor (ADP) and analyzed using Summit software. Neutrophils were classified as either LCA+ CD11c+ or LCA+ CD11c− Gr1+. Monocytes were classified as LCA+ CD11c− CD11b+. T cells were classified as LCA+ CD3e+ and either CD4+ or CD8+. B cells were classified as LCA+ CD3e− B220+. NK cells were classified as LCA+ CD3e− NK1.1+.
Quantitative real-time PCR.
Mice were sacrificed and perfused intracardially with 1× PBS. RNA was extracted from cells and tissues using TRIzol (Ambion). Tissues were dissociated by homogenization prior to RNA extraction. Superscript III reverse transcriptase (Invitrogen) was used to generate cDNA by random priming from a total of 10 μg RNA from each sample. Real-time PCR was performed using ABI Prism 7300 sequence detection system software (v1.4.0) and TaqMan Gene Expression master mix (Applied Biosystems). For absolute quantification of viral RNA, CHIKV sequence-specific primer probes were used as described previously (29). A standard curve was run in tandem using CHIKV plasmid. For quantification of host transcripts, relative quantification was performed using the ΔΔCT method (where CT is threshold cycle). For all PCR targets, quantification was normalized to the amount of 18S rRNA present in the sample. Absolute quantification of 18S was performed using a standard curve.
Cytokine and chemokine protein quantification.
Protein levels of cytokines/chemokines in clarified tissue homogenates were evaluated using a multiplex bead array assay. All the antibodies and cytokine standards were purchased as antibody pairs from R&D Systems or PeproTech. Individual magnetic bead regions (Luminex Corp.) were coupled to cytokine-specific capture antibodies according to the manufacturer’s recommendations. Conjugated beads were washed and kept at 4°C until use. Biotinylated polyclonal antibodies were used at twice the concentrations recommended for a classical enzyme-linked immunosorbent assay (ELISA) according to the manufacturer. All assay procedures were performed in assay buffer containing PBS supplemented with 1% normal mouse serum (Invitrogen), 1% normal goat serum (Invitrogen), and 20 mM Tris-HCl (pH 7.4). The assays were run using 1,500 beads per each set of cytokines measured per well in a total volume of 50 µl. A total of 50 μl of each sample was added to the well and incubated overnight at 4°C. After being washed, the beads were resuspended in 50 μl of assay buffer containing biotinylated polyclonal antibodies against the measured cytokines for 1 h at room temperature, washed again, and then resuspended in 50 μl of assay buffer containing 1 μg/ml solution of streptavidin-PE (Invitrogen). The plates were read on a Luminex MAGPIX platform. For each bead set, >50 beads were collected. The median fluorescence intensity of these beads was recorded and used for analysis with the Milliplex software using a 5P regression algorithm.
Statistical analyses.
All data were analyzed in the statistical programing language R (v.3.0.2). Where indicated in the figures, analysis of variance (ANOVA) was used to determine statistical differences between data sets; Tukey’s honestly significant differences method was used post hoc to correct for multiple comparisons. Where applicable, * indicates a P value of less than 0.05 and ** indicates a P value of less than 0.01. Multiplex array data were analyzed by a nonparametric Mann-Whitney U test. The false-discovery rate was set to 0.1, and significance was determined using the Benjamini-Hochberg method for multiple-comparison corrections. Where applicable, * indicates significance under these criteria.
ACKNOWLEDGMENTS
We thank Michael Diamond of Washington University for generously providing us with a sample of the clinical isolate of the Caribbean strain of CHIKV. We further thank Kenneth Plante of the University of Texas Medical Branch for providing us with the passage history of the Caribbean strain. We thank Heise lab members for contributing thoughtfully to scientific discussions. In particular, we thank Martin Ferris and Paul Maurizio for discussion of statistical analyses. We also thank the UNC Animal histopathology and UNC flow cytometry core facilities for the use of their equipment and services.
The UNC flow cytometry core facility is supported in part by Cancer Center Core support grant P30 CA016086 to the UNC Lineberger Comprehensive Cancer Center. This work was supported by the National Institutes of Health (grants U54 AI 057157-07, R21 AI 094500-01, U19 AI 109680, and U19 AI 109761, as well as NRSA fellowship F31 AI 114231-01, which was awarded to J.E.J.). W.S. and N.M. were supported by funds from the University Cancer Research Fund. J.E.J. and M.T.H. contributed to the funding of this study. The funders (other than J.E.J. and M.T.H.) had no role in study design, data collection and interpretation, or the decision to submit the work for publication. We declare no competing financial interests.
J.E.J., K.M.L., and M.T.H. contributed to the study design and data interpretation. J.E.J., K.M.L., A.C.W., W.S., L.R.T., J.A.B., C.R.M., and C.B. performed experiments. J.E.J. and K.M.P. contributed to data analysis. N.M. and J.K.L. contributed resources and generated data.
Footnotes
Citation Jones JE, Long KM, Whitmore AC, Sanders W, Thurlow LR, Brown JA, Morrison CR, Vincent H, Peck KM, Browning C, Moorman N, Lim JK, Heise MT. 2017. Disruption of the opal stop codon attenuates Chikungunya virus-induced arthritis and pathology. mBio 8:e01456-17. https://doi.org/10.1128/mBio.01456-17.
REFERENCES
- 1.Soumahoro MK, Boelle PY, Gaüzere BA, Atsou K, Pelat C, Lambert B, La Ruche G, Gastellu-Etchegorry M, Renault P, Sarazin M, Yazdanpanah Y, Flahault A, Malvy D, Hanslik T. 2011. The chikungunya epidemic on la Réunion Island in 2005–2006: a cost-of-illness study. PLoS Neglect Trop Dis 5:e1197. doi: 10.1371/journal.pntd.0001197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gutierrez-Saravia E, Gutierrez CE. 2015. Chikungunya virus in the Caribbean: a threat for all of the Americas. J Pediatr Infect Dis Soc 4:1–3. doi: 10.1093/jpids/piv002. [DOI] [PubMed] [Google Scholar]
- 3.Strauss JH, Strauss EG. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58:491–562. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.de Groot RJ, Hardy WR, Shirako Y, Strauss JH. 1990. Cleavage-site preferences of Sindbis virus polyproteins containing the non-structural proteinase. Evidence for temporal regulation of polyprotein processing in vivo. EMBO J 9:2631–2638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Firth AE, Chung BY, Fleeton MN, Atkins JF. 2008. Discovery of frameshifting in Alphavirus 6K resolves a 20-year enigma. Virol J 5:108. doi: 10.1186/1743-422X-5-108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Snyder JE, Kulcsar KA, Schultz KL, Riley CP, Neary JT, Marr S, Jose J, Griffin DE, Kuhn RJ. 2013. Functional characterization of the Alphavirus TF protein. J Virol 87:8511–8523. doi: 10.1128/JVI.00449-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Melancon P, Garoff H. 1987. Processing of the Semliki Forest virus structural polyprotein: role of the capsid protease. J Virol 61:1301–1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Thomas S, Rai J, John L, Günther S, Drosten C, Pützer BM, Schaefer S. 2010. Functional dissection of the Alphavirus capsid protease: sequence requirements for activity. Virol J 7:327. doi: 10.1186/1743-422X-7-327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Suthar MS, Shabman R, Madric K, Lambeth C, Heise MT. 2005. Identification of adult mouse neurovirulence determinants of the Sindbis virus strain AR86. J Virol 79:4219–4228. doi: 10.1128/JVI.79.7.4219-4228.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. 2007. A single mutation in Chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 3:e201. doi: 10.1371/journal.ppat.0030201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Chen R, Wang E, Tsetsarkin KA, Weaver SC. 2013. Chikungunya virus 3′ untranslated region: adaptation to mosquitoes and a population bottleneck as major evolutionary forces. PLoS Pathog 9:e1003591. doi: 10.1371/journal.ppat.1003591. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Fayzulin R, Frolov I. 2004. Changes of the secondary structure of the 5′ end of the Sindbis virus genome inhibit virus growth in mosquito cells and lead to accumulation of adaptive mutations. J Virol 78:4953–4964. doi: 10.1128/JVI.78.10.4953-4964.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Cruz CC, Suthar MS, Montgomery SA, Shabman R, Simmons J, Johnston RE, Morrison TE, Heise MT. 2010. Modulation of type I IFN induction by a virulence determinant within the Alphavirus nsP1 protein. Virology 399:1–10. doi: 10.1016/j.virol.2009.12.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Simmons JD, Wollish AC, Heise MT. 2010. A determinant of Sindbis virus neurovirulence enables efficient disruption of Jak/STAT signaling. J Virol 84:11429–11439. doi: 10.1128/JVI.00577-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Shabman RS, Rogers KM, Heise MT. 2008. Ross River virus envelope glycans contribute to type I interferon production in myeloid dendritic cells. J Virol 82:12374–12383. doi: 10.1128/JVI.00985-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Shabman RS, Morrison TE, Moore C, White L, Suthar MS, Hueston L, Rulli N, Lidbury B, Ting JP, Mahalingam S, Heise MT. 2007. Differential induction of type I interferon responses in myeloid dendritic cells by mosquito and mammalian-cell-derived alphaviruses. J Virol 81:237–247. doi: 10.1128/JVI.01590-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gorchakov R, Frolova E, Frolov I. 2005. Inhibition of transcription and translation in Sindbis virus-infected cells. J Virol 79:9397–9409. doi: 10.1128/JVI.79.15.9397-9409.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Fros JJ, Domeradzka NE, Baggen J, Geertsema C, Flipse J, Vlak JM, Pijlman GP. 2012. Chikungunya virus nsP3 blocks stress granule assembly by recruitment of G3BP into cytoplasmic foci. J Virol 86:10873–10879. doi: 10.1128/JVI.01506-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Panas MD, Ahola T, McInerney GM. 2014. The C-terminal repeat domains of nsP3 from the Old World alphaviruses bind directly to G3BP. J Virol 88:5888–5893. doi: 10.1128/JVI.00439-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Stapleford KA, Moratorio G, Henningsson R, Chen R, Matheus S, Enfissi A, Weissglas-Volkov D, Isakov O, Blanc H, Mounce BC, Dupont-Rouzeyrol M, Shomron N, Weaver S, Fontes M, Rousset D, Vignuzzi M. 2016. Whole-genome sequencing analysis from the Chikungunya virus Caribbean outbreak reveals novel evolutionary genomic elements. PLoS Neglect Trop Dis 10:e0004402. doi: 10.1371/journal.pntd.0004402. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Assunção-Miranda I, Cruz-Oliveira C, Da Poian AT. 2013. Molecular mechanisms involved in the pathogenesis of Alphavirus-induced arthritis. Biomed Res Int 2013:973516. doi: 10.1155/2013/973516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Broeckel R, Haese N, Messaoudi I, Streblow DN. 2015. Nonhuman primate models of Chikungunya virus infection and disease (CHIKV NHP model). Pathogens 4:662–681. doi: 10.3390/pathogens4030662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Teo TH, Her Z, Tan JJ, Lum FM, Lee WW, Chan YH, Ong RY, Kam YW, Leparc-Goffart I, Gallian P, Rénia L, de Lamballerie X, Ng LFP. 2015. Caribbean and La Réunion Chikungunya virus isolates differ in their capacity to induce proinflammatory Th1 and NK cell responses and acute joint pathology. J Virol 89:7955–7969. doi: 10.1128/JVI.00909-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Parola P, de Lamballerie X, Jourdan J, Rovery C, Vaillant V, Minodier P, Brouqui P, Flahault A, Raoult D, Charrel RN. 2006. Novel Chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 12:1493–1499. doi: 10.3201/eid1210.060610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Chen KC, Kam YW, Lin RT, Ng MM, Ng LF, Chu JJ. 2013. Comparative analysis of the genome sequences and replication profiles of Chikungunya virus isolates within the East, Central and South African (ECSA) lineage. Virol J 10:169. doi: 10.1186/1743-422X-10-169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Li GP, Rice CM. 1989. Mutagenesis of the in-frame opal termination codon preceding nsP4 of Sindbis virus: studies of translational readthrough and its effect on virus replication. J Virol 63:1326–1337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Levinson RS, Strauss JH, Strauss EG. 1990. Complete sequence of the genomic RNA of O’nyong-nyong virus and its use in the construction of Alphavirus phylogenetic trees. Virology 175:110–123. doi: 10.1016/0042-6822(90)90191-S. [DOI] [PubMed] [Google Scholar]
- 28.Myles KM, Kelly CL, Ledermann JP, Powers AM. 2006. Effects of an opal termination codon preceding the nsP4 gene sequence in the o’nyong-nyong virus genome on Anopheles gambiae infectivity. J Virol 80:4992–4997. doi: 10.1128/JVI.80.10.4992-4997.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Morrison TE, Oko L, Montgomery SA, Whitmore AC, Lotstein AR, Gunn BM, Elmore SA, Heise MT. 2011. A mouse model of Chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol 178:32–40. doi: 10.1016/j.ajpath.2010.11.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Li G, Rice CM. 1993. The signal for translational readthrough of a UGA codon in Sindbis virus RNA involves a single cytidine residue immediately downstream of the termination codon. J Virol 67:5062–5067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Crow JP, Beckman JS. 1995. Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Adv Pharmacol 34:17–43. doi: 10.1016/S1054-3589(08)61079-0. [DOI] [PubMed] [Google Scholar]
- 32.Crow JP, Beckman JS. 1995. The role of peroxynitrite in nitric oxide-mediated toxicity, p 57–73. In Koprowski H, Maeda H (ed), The role of nitric oxide in physiology and pathophysiology. Springer, Berlin, Germany. [DOI] [PubMed] [Google Scholar]
- 33.Kaur H, Halliwell B. 1994. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 350:9–12. doi: 10.1016/0014-5793(94)00722-5. [DOI] [PubMed] [Google Scholar]
- 34.ter Steege JC, Koster-Kamphuis L, van Straaten EA, Forget PP, Buurman WA. 1998. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radic Biol Med 25:953–963. doi: 10.1016/S0891-5849(98)00184-1. [DOI] [PubMed] [Google Scholar]
- 35.Burrack KS, Tan JJ, McCarthy MK, Her Z, Berger JN, Ng LF, Morrison TE. 2015. Myeloid cell Arg1 inhibits control of arthritogenic alphavirus infection by suppressing antiviral T Cells. PLoS Pathog 11:e1005191. doi: 10.1371/journal.ppat.1005191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Long KM, Ferris MT, Whitmore AC, Montgomery SA, Thurlow LR, McGee CE, Rodriguez CA, Lim JK, Heise MT. 2015. γδ T cells play a protective role in Chikungunya virus-induced disease. J Virol 90:433–443. doi: 10.1128/JVI.02159-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Teo T-H, Lum F-M, Claser C, Lulla V, Lulla A, Merits A, Rénia L, Ng LFP. 2013. A pathogenic role for CD4+ T cells during chikungunya virus infection in mice. J Immunol 190:259–269. doi: 10.4049/jimmunol.1202177. [DOI] [PubMed] [Google Scholar]
- 38.Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, Schroder WA, Higgs S, Suhrbier A. 2010. Chikungunya virus arthritis in adult wild-type mice. J Virol 84:8021–8032. doi: 10.1128/JVI.02603-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, Barkham T, Yang H, Rénia L, Leo YS, Ng LFP. 2011. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis 203:149–157. doi: 10.1093/infdis/jiq042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Ng LFP, Chow A, Sun YJ, Kwek DJ, Lim PL, Dimatatac F, Ng LC, Ooi EE, Choo KH, Her Z, Kourilsky P, Leo YS. 2009. IL-1beta, IL-6, and RANTES as biomarkers of chikungunya severity. PLoS One 4:e4261. doi: 10.1371/journal.pone.0004261. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Tuittila M, Hinkkanen AE. 2003. Amino acid mutations in the replicase protein nsP3 of Semliki Forest virus cumulatively affect neurovirulence. J Gen Virol 84:1525–1533. doi: 10.1099/vir.0.18936-0. [DOI] [PubMed] [Google Scholar]
- 42.Sanders WA, Long K, Rivera B, Vincent HA, Heise MT, Rodriguez-Orengo JF, Moorman NJ. 2017. Complete genome sequences of 15 Chikungunya virus isolates from Puerto Rico. Genome Announc 5:e00561-17. doi: 10.1128/genomeA.00561-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Chopra A, Saluja M, Venugopalan A. 2014. Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following Chikungunya virus infection. Arthritis Rheumatol 66:319–326. doi: 10.1002/art.38221. [DOI] [PubMed] [Google Scholar]
- 44.Ashbrook AW, Lentscher AJ, Zamora PF, Silva LA, May NA, Bauer JA, Morrison TE, Dermody TS. 2016. Antagonism of the sodium-potassium ATPase impairs Chikungunya virus infection. mBio 7:e00693-16. doi: 10.1128/mBio.00693-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Mounce BC, Poirier EZ, Passoni G, Simon-Loriere E, Cesaro T, Prot M, Stapleford KA, Moratorio G, Sakuntabhai A, Levraud JP, Vignuzzi M. 2016. Interferon-induced spermidine-spermine acetyltransferase and polyamine depletion restrict Zika and chikungunya viruses. Cell Host Microbe 20:167–177. doi: 10.1016/j.chom.2016.06.011. [DOI] [PubMed] [Google Scholar]
- 46.Mounce BC, Cesaro T, Vlajnić L, Vidiņa A, Vallet T, Weger-Lucarelli J, Passoni G, Stapleford KA, Levraud JP, Vignuzzi M. 2017. Chikungunya virus overcomes polyamine depletion by mutation of nsP1 and the opal stop codon to confer enhanced replication and fitness. J Virol 91:e00344-17. doi: 10.1128/JVI.00344-17. [DOI] [PMC free article] [PubMed] [Google Scholar]